Foghorn’s Phase I AML/MDS trial on FDA partial clinical hold due to subject death
No new subjects will be enrolled in the trial until the FDA lifts the partial clinical hold.

No new subjects will be enrolled in the trial until the FDA lifts the partial clinical hold.
The trial assessed the efficacy and tolerability of navitoclax alone or with ruxolitinib for myelofibrosis treatment.
Bristol Myers Squibb, GT Biopharma, and Gemini Therapeutics terminate early-phase trials of their respective assets.
ByFindings showed that bentracimab treatment substantially restored platelet function within five minutes of dosing.
The latest development comes after the company reported the death of a patient with R/R AML.
The open-label trial will have dose-escalation and dose-expansion portions to analyse DSP-5336 in AML or ALL patients.
The trial was initiated after the company obtained approval from China’s National Medical Products Administration.
The Phase Ib FRIDA trial will assess iadademstat plus gilteritinib to treat R/R AML FLT3mut+ patients.